A citation-based method for searching scientific literature

Ke Wang, Juan Li, Jianguo Sun, Li Li, Xi Zhang, Jianyong Zhang, Min Yu, Xianwei Ye, Ming Zhang, Yu Zhang, Wenxiu Yao, Meijuan Huang. Zhongguo Fei Ai Za Zhi 2021
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.
Alice T Shaw, Todd M Bauer, Filippo de Marinis, Enriqueta Felip, Yasushi Goto, Geoffrey Liu, Julien Mazieres, Dong-Wan Kim, Tony Mok, Anna Polli,[...]. N Engl J Med 2020
292
100

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Hyuna Sung, Jacques Ferlay, Rebecca L Siegel, Mathieu Laversanne, Isabelle Soerjomataram, Ahmedin Jemal, Freddie Bray. CA Cancer J Clin 2021
100

Chest CT Diagnosis and Clinical Management of Drug-Related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper From the Fleischner Society.
Takeshi Johkoh, Kyung Soo Lee, Mizuki Nishino, William D Travis, Jay H Ryu, Ho Yun Lee, Christopher J Ryerson, Tomás Franquet, Alexander A Bankier, Kevin K Brown,[...]. Chest 2021
22
100


Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System.
Monia Sisi, Michele Fusaroli, Andrea De Giglio, Francesco Facchinetti, Andrea Ardizzoni, Emanuel Raschi, Francesco Gelsomino. Target Oncol 2022
4
100


HRCT Patterns of Drug-Induced Interstitial Lung Diseases: A Review.
Giulio Distefano, Luigi Fanzone, Monica Palermo, Francesco Tiralongo, Salvatore Cosentino, Corrado Inì, Federica Galioto, Ada Vancheri, Sebastiano E Torrisi, Letizia A Mauro,[...]. Diagnostics (Basel) 2020
14
100

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.
François Mach, Colin Baigent, Alberico L Catapano, Konstantinos C Koskinas, Manuela Casula, Lina Badimon, M John Chapman, Guy G De Backer, Victoria Delgado, Brian A Ference,[...]. Eur Heart J 2020
100

Comparative psychometric analyses of the SCL-90-R and its short versions in patients with affective disorders.
Ulrich Prinz, Detlev O Nutzinger, Holger Schulz, Franz Petermann, Christoph Braukhaus, Sylke Andreas. BMC Psychiatry 2013
114
100

Clinical Management of Adverse Events Associated with Lorlatinib.
Todd M Bauer, Enriqueta Felip, Benjamin J Solomon, Holger Thurm, Gerson Peltz, Marc D Chioda, Alice T Shaw. Oncologist 2019
51
100

Monitoring and Managing Lorlatinib Adverse Events in the Portuguese Clinical Setting: A Position Paper.
Fernando Barata, Carlos Aguiar, Tiago Reis Marques, José Bravo Marques, Venceslau Hespanhol. Drug Saf 2021
3
100


Treatment of cognitive deficits in brain tumour patients: current status and future directions.
Marijke B Coomans, Sophie D van der Linden, Karin Gehring, Martin J B Taphoorn. Curr Opin Oncol 2019
39
100

2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee.
Salim S Virani, Pamela B Morris, Anandita Agarwala, Christie M Ballantyne, Kim K Birtcher, Penny M Kris-Etherton, Amanda B Ladden-Stirling, Michael Miller, Carl E Orringer, Neil J Stone. J Am Coll Cardiol 2021
54
100

Consensus Recommendations for Management and Counseling of Adverse Events Associated With Lorlatinib: A Guide for Healthcare Practitioners.
Mollie Reed, Aimee-Lauren S Rosales, Marc D Chioda, Lindsey Parker, Geeta Devgan, Jacob Kettle. Adv Ther 2020
15
100

Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC.
Qian Zhu, Hao Hu, De-Sheng Weng, Xiao-Fei Zhang, Chang-Long Chen, Zi-Qi Zhou, Yan Tang, Jian-Chuan Xia. BMC Cancer 2017
20
100

Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety From a Phase 2 Study in People's Republic of China.
Shun Lu, Qing Zhou, Xiaoqing Liu, Yingying Du, Yun Fan, Ying Cheng, Jian Fang, You Lu, Cheng Huang, Jianying Zhou,[...]. J Thorac Oncol 2022
3
100

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.
Ryohei Katayama, Alice T Shaw, Tahsin M Khan, Mari Mino-Kenudson, Benjamin J Solomon, Balazs Halmos, Nicholas A Jessop, John C Wain, Alan Tien Yeo, Cyril Benes,[...]. Sci Transl Med 2012
943
100

Cancer statistics in China and United States, 2022: profiles, trends, and determinants.
Changfa Xia, Xuesi Dong, He Li, Maomao Cao, Dianqin Sun, Siyi He, Fan Yang, Xinxin Yan, Shaoli Zhang, Ni Li,[...]. Chin Med J (Engl) 2022
193
100

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.
Justin F Gainor, Leila Dardaei, Satoshi Yoda, Luc Friboulet, Ignaty Leshchiner, Ryohei Katayama, Ibiayi Dagogo-Jack, Shirish Gadgeel, Katherine Schultz, Manrose Singh,[...]. Cancer Discov 2016
675
100

The mini-cog: a cognitive 'vital signs' measure for dementia screening in multi-lingual elderly.
S Borson, J Scanlan, M Brush, P Vitaliano, A Dokmak. Int J Geriatr Psychiatry 2000
779
100


Proactive Rehabilitation for Chemotherapy-Induced Peripheral Neuropathy.
Robert Knoerl, Laura Gilchrist, Grace A Kanzawa-Lee, Clare Donohoe, Celia Bridges, Ellen M Lavoie Smith. Semin Oncol Nurs 2020
7
100

Catalog of Lung Cancer Gene Mutations Among Chinese Patients.
Xinying Xue, Idorenyin Asuquo, Lei Hong, Jie Gao, Zhouhuan Dong, Li Pang, Tianjiao Jiang, Mingming Meng, Jingbo Fan, Jiaxin Wen,[...]. Front Oncol 2020
9
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.